IndustryCompany release

Nuvation Bio reports $27.5M IBTROZI sales as FDA updates label and grants safusidenib Fast Track

🇺🇸 Nuvation Bio Inc. (NUVB) · Wed 04 Nov 2026

The US biotech posted $45.0m in third-quarter revenue, while FDA approved a label update for its ROS1+ lung cancer drug four months ahead of schedule.

Nuvation Bio reported third-quarter 2026 results on 4 November, with total revenue of $45.0 million. Net US sales of IBTROZI (taletrectinib), its treatment for ROS1-positive non-small cell lung cancer (NSCLC), accounted for $27.5 million of that figure.

On the regulatory side, the US Food and Drug Administration approved a supplemental new drug application (sNDA) for IBTROZI in September, about four months before the agency's target action date. The update revises the label to show a median duration of response of 49.7 months in patients who had not previously received a tyrosine kinase inhibitor (TKI-naïve).

In August, the FDA also granted Fast Track Designation to safusidenib for IDH1-mutant glioma. Fast Track is a programme intended to speed development and review of drugs for serious conditions with unmet medical need, and it allows more frequent interaction with the agency.

The company ended the quarter with cash and securities of $663.4 million. The summary provided does not give further detail on guidance, pricing or safusidenib's development stage.

What it means for your team

  • The early sNDA approval shows the FDA can act well ahead of target dates on label updates backed by mature efficacy data, a point for regulatory planning timelines.
  • The label now carries a 49.7-month median duration of response in TKI-naïve ROS1+ NSCLC patients, which market-access teams may cite in payer and formulary discussions.
  • Fast Track for safusidenib in IDH1-mutant glioma signals a potential for closer FDA engagement as development proceeds, though it does not guarantee approval.

Company's press release (SEC filing): Nuvation Bio Inc. ↗

Article written by VigiEye from the official source (Nuvation Bio Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →